Also known as: Alendronate sodium
Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Alendronic acid is the active ingredient of these drugs:
Spain
Turkey
Romania
South Africa
Hong Kong
Turkey
Brazil
Hong Kong
Poland
New Zealand
Hong Kong
Poland
Italy
Ecuador
Italy
Estonia
Hong Kong South Africa
Turkey
Ecuador
Italy
Hong Kong
Cyprus Estonia Finland Germany Ireland
Turkey
Brazil
Brazil
France Ireland Netherlands
Turkey
Turkey
Brazil
Turkey
South Africa
Tunisia
Australia South Africa
Italy
Ecuador
Brazil
Ecuador
South Africa
Australia
Turkey
South Africa
Tunisia
Austria Brazil Canada France Germany
Turkey
South Africa
Ireland
Italy
South Africa
Italy
Brazil
Cyprus
Turkey
Singapore
Estonia
Ecuador
Italy
Brazil
Hong Kong
South Africa
Italy
Italy
Austria
South Africa
Ecuador
Brazil
Lithuania Poland
South Africa
Brazil
Poland
South Africa
Brazil
Brazil
Hong Kong
Turkey
Ireland
Ecuador
Austria
South Africa
Ecuador
Poland
South Africa
Brazil
Ecuador
Italy
Italy
Hong Kong
South Africa
Ireland
Estonia Poland
Spain
Spain
Estonia France
Romania
Estonia Germany Hong Kong Ireland
Turkey
Alendronic acid is also found within below combination drugs:
ADROVANCE , ALEFORT , ALENCALCI D3 , ALENDIL D , BENTEXO , BONENDRO , BONENORM , BONEX-D , BONMEGA , BONYL , BONYL PLUS , DA-BONE , FONATPLUS , FOSALEN D3 , FOSAMAX D , FOSAMAX PLUS , FOSASTAD , FOSAVANCE , OSSOFORTIN A , OSTEOCAL , OSTEOMIX PLUS , OSTEONATE PLUS , OSTEOPLUS D , OSVIPAC , TEBONEVA , TRIDEPOS , VANTAVO , VEGABON PLUS D